WEREWOLF THERAPEUTICS, INC. Investment Income, Interest
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Investment Income, Interest of $277.00 thousand for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-06-30 was $277.00K, a 67.41% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-03-31 was $433.00K, a 56.57% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-12-31 was $564.00K, a 56.91% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-09-30 was $697.00K, a 56.38% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. investment income, interest for fiscal 2023 was $7.42M, a 288.68% increase from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. investment income, interest for fiscal 2022 was $1.91M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $277.00K S-4 · filed 2026-09-22 | $710.00K S-4 · filed 2026-09-22 | $1.27M derived: sum of 3 quarters · filed 2026-09-22 | $1.97M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | $433.00K 10-Q · filed 2026-05-07 | $997.00K derived: sum of 2 quarters · filed 2026-09-22 | $1.69M derived: sum of 3 quarters · filed 2026-09-22 | $2.54M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $564.00K derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $1.26M derived: sum of 2 quarters · filed 2026-09-22 | $2.11M derived: sum of 3 quarters · filed 2026-09-22 | $3.11M S-4 · filed 2026-09-22 |
| 2025-09-30 | $697.00K 10-Q · filed 2025-11-04 | $1.55M derived: sum of 2 quarters · filed 2026-09-22 | $2.54M 10-Q · filed 2025-11-04 | $3.85M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $850.00K S-4 · filed 2026-09-22 | $1.85M S-4 · filed 2026-09-22 | $3.16M derived: sum of 3 quarters · filed 2026-09-22 | $4.75M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $997.00K 10-Q · filed 2026-05-07 | $2.31M derived: sum of 2 quarters · filed 2026-09-22 | $3.90M derived: sum of 3 quarters · filed 2026-09-22 | $5.70M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | $1.31M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $2.91M derived: sum of 2 quarters · filed 2026-09-22 | $4.70M derived: sum of 3 quarters · filed 2026-09-22 | $6.67M S-4 · filed 2026-09-22 |
| 2024-09-30 | $1.60M 10-Q · filed 2025-11-04 | $3.39M derived: sum of 2 quarters · filed 2025-11-04 | $5.36M 10-Q · filed 2025-11-04 | $7.34M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $1.79M 10-Q · filed 2025-08-14 | $3.77M 10-Q · filed 2025-08-14 | $5.74M derived: sum of 3 quarters · filed 2025-08-14 | $7.71M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.97M 10-Q · filed 2025-05-08 | $3.95M derived: sum of 2 quarters · filed 2025-05-08 | $5.92M derived: sum of 3 quarters · filed 2025-05-08 | $7.87M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.95M derived: sum of 2 quarters · filed 2025-03-11 | $5.90M derived: sum of 3 quarters · filed 2025-03-11 | $7.42M 10-K · filed 2025-03-11 |
| 2023-09-30 | $1.97M 10-Q · filed 2024-11-07 | $3.92M derived: sum of 2 quarters · filed 2024-11-07 | $5.44M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.95M 10-Q · filed 2024-08-08 | $3.47M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $1.52M 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | $1.91M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |